Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
Landscape of Singapore business building around Marina bay. Albatroz Therapeutics is based in Singapore. Credit: MOLPIX via Shutterstock Albatroz Therapeutics announced a successful $3 million financing round on April 26. This investment will be used to further the development of the Singapore-based pharmaceutical company’s solid tumour-focused monoclonal antibodies. The funding and a prize-win from Amgen will support the company’s drug development plans as Singapore continues developing its pharmaceutical market. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
ReportsInnovation in Pharmaceuticals: Anti-HIV compositions GlobalData
View allCompanies IntelligenceSeeds Capital Pte LtdAlbatroz Therapeutics Pte LtdOutram Bio Pte LtdView all Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.
Outram Bio and SEEDS Capital led the successful funding round. SEEDs Capital is an investment arm of Enterprise Singapore that supports early-stage technology startups. In the press release, the company announced that Amgen granted Albatroz the first Golden Ticket prize in Singapore for its science and business plan. The Amgen Golden Ticket awards support to early life science businesses by offering them resources for business development. In this case, Albatroz has been rewarded with access to a fully equipped, turnkey, and certified BSL-2 laboratory from NSG Biolabs. Albatroz Therapeutics is developing first-in-class antibody therapeutics for solid tumours and arthritic disorders. The company targets disease through mechanisms in the extracellular matrix (ECM), where Albatroz’s medicines target and degrade a protein complex, Calnexin. This protein complex is activated by a glycosylation pathway involved in the pathogenesis of these diseases. In solid tumours, this action prevents ECM degradation and tumour growth, which in arthritis, this prevents the destruction of cartilage ECM. This news arrives as there is a larger push to develop Singapore’s pharmaceutical industry. In December 2022, GSK, Sanofi and Takeda entered an agreement with a partnership of agencies to further biologic manufacturing in Singapore. The country is also an attractive site for handling operations in Asia as Novo Nordisk and GSK have opened regional headquarters there. The country is also developing its pharmaceutical market through the Pharma Innovation Programme Singapore (PIPS), which supports Singapore’s manufacturing and data analytics capabilities.
As of April 13, GlobalData calculates that the country’s overall market access risk score as 2.32. Market access risk scores consider quantitative and qualitative factors that affect market access to give an overall score denoting the stability of the pharmaceutical market access environment in a country. The scale goes from one to ten with a lower score ranking a more stable market.
A partner at Outram Bio, Christopher Tan said, “Albatroz Therapeutics is an exciting example of the burgeoning biotech industry in Singapore– Southeast Asia’s largest biotech hub, and one that boasts cutting-edge research and attracts leading scientists from around the world”. How is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Please check your email to download the Report.